研究单位：[1]Ipsen[2]Affiliated Hospital of Hebei University,Baoding,China[3]Beijing Hospital,Beijing,China[4]Peking University First Hospital,Beijing,China[5]Peking University People's Hospital,Beijing,China[6]Hunan Cancer Hospital,Changsha,China[7]West China Hospital of Sichuan University,Chengdu,China[8]Chongqing University Cancer Hospital,Chongqing,China[9]The First Affiliated Hospital of Chongqing Medical University,Chongqing,China[10]Deyang People's Hospital,Deyang,China[11]Sun Yat-Sen University Cancer Center,Guangzhou,China[12]Guizhou Provincial People's Hospital,Guiyang,China[13]The Affiliated Hospital of Guizhou Medical University,Guiyang,China[14]The First Affiliated Hospital, Zhejiang University School of Medicine,Hangzhou,China[15]Qilu Hospital of Shandong University,Jinan,China[16]Shandong Provincial Hospital,Jinan,China[17]Nanjing Drum Tower Hospital,Nanjing,China[18]Zhongda Hospital Southeast University,Nanjing,China[19]Ningbo First Hospital,Ningbo,China[20]Fudan University Shang Hai Cancer Center,Shanghai,China[21]Shanghai Fifth People's Hospital,Shanghai,China[22]Shanghai Tongji Hospital,Shanghai,China[23]Liaoning Cancer Hospital & Institute,Shenyang,China[24]The First Hospital of China Medical University,Shenyang,China[25]Peking University Shenzhen Hospital,Shenzhen,China[26]Suining Central Hospital,Suining,China[27]The Second Affiliated Hospital of Soochow University,Suzhou,China[28]Tianjin Cancer Hospital,Tianjin,China[29]The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China[30]The First Affiliated Hospital of Wannan Medical College,Wuhu,China[31]The Second Affiliated Hospital of Wannan Medical College,Wuhu,China[32]Wuxi People's Hospital,Wuxi,China[33]Subei People's Hospital,Yangzhou,China[34]Yantai Yuhuangding Hospital,Yantai,China[35]Henan Cancer Hospital,Zhengzhou,China[36]Zigong First People's Hospital,Zigong,China
研究目的：
The main aim of this study is to assess the effectiveness and safety of the 6-month formulation of triptorelin pamoate in Chinese participants with locally advanced or metastatic cancer of the prostate. Participants will receive 1 injection of triptorelin pamoate 6-month formulation.
